Royce & Associates LP Invests $1.54 Million in Compass Therapeutics, Inc. $CMPX

Royce & Associates LP purchased a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 285,988 shares of the company’s stock, valued at approximately $1,536,000.

A number of other large investors have also made changes to their positions in CMPX. Russell Investments Group Ltd. increased its position in shares of Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares in the last quarter. Creative Planning acquired a new position in shares of Compass Therapeutics during the second quarter worth $30,000. Flagship Harbor Advisors LLC acquired a new position in shares of Compass Therapeutics during the fourth quarter worth $32,000. Strs Ohio acquired a new position in shares of Compass Therapeutics during the first quarter worth $34,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of Compass Therapeutics during the third quarter worth $37,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CMPX. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Monday, April 20th. Craig Hallum began coverage on Compass Therapeutics in a research report on Friday, February 13th. They issued a “buy” rating and a $15.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Guggenheim reissued a “buy” rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Finally, Wall Street Zen downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.60.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.38 on Friday. The stock’s fifty day moving average price is $3.81 and its 200 day moving average price is $4.95. Compass Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $6.88. The company has a market cap of $428.61 million, a price-to-earnings ratio of -5.80 and a beta of 0.79.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Research analysts expect that Compass Therapeutics, Inc. will post -0.44 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.